Evaluation of a new enzyme immunoassay based on recombinant Rubella virus-like particles for detection of immunoglobulin M antibodies to Rubella virus.
A new enzyme immunoassay for the detection of specific antibodies to rubella virus was evaluated at two different sites. This assay, the Roche Cobas Core Rubella IgM EIA recomb, uses a recombinant rubella virus-like particle and is based upon the immunoglobulin M (IgM) capture principle. It was compared to the Abbott IMx Rubella IgM test and to the Sorin ETI-RUBEK-M reverse test. The relative clinical specificities were 99.30% for the Roche test, 98.26% for the Abbott test, and 100% for the Sorin test. The relative clinical sensitivities were 100, 93.87, and 82.65%, respectively. In the case of most primary infections, IgM antibodies could be detected immediately at the onset of the disease and for up to 7 weeks. In the case of vaccinations, they could be detected between 3 and 12 weeks after vaccination.
Grangeot-Keros
L
L
Department of Microbiology and Immunology, Hôpital Antoine Béclère, Clamart, France.
Enders
G
G
D000208:Acute Disease; D000914:Antibodies, Viral / Q000097:blood*; D005069:Evaluation Studies as Topic; D005189:False Positive Reactions; D006801:Humans; D007124:Immunoenzyme Techniques; D007075:Immunoglobulin M / Q000097:blood*; D011994:Recombinant Proteins / Q000276:immunology; D012217:Rheumatoid Factor / Q000032:analysis; D012409:Rubella / Q000175:diagnosis*; D012411:Rubella Vaccine / Q000276:immunology*; D012412:Rubella virus / Q000276:immunology*; D012680:Sensitivity and Specificity; D014611:Vaccination; D014764:Viral Proteins / Q000276:immunology
D000914:Antibodies, Viral; D007075:Immunoglobulin M; D011994:Recombinant Proteins; D012411:Rubella Vaccine; D014764:Viral Proteins; C040901:rubella antibodies; D012217:Rheumatoid Factor